DDInter120 DDInter740
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Arsenic trioxide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Flecainide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Triclabendazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Perflutren
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Arsenic trioxide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Flecainide (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Perflutren and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)